Cannabis

NanoSphere Health Sciences Awarded Breakthrough Patent – $NSHS

LANDMARK PATENT MARKS MOST SIGNIFICANT ADVANCEMENT IN OVER 25 YEARS FOR NON-INVASIVE MEDICAL DELIVERY SYSTEM

Denver (March 27, 2018) – NanoSphere Health Sciences Inc (CSE: NSHS) (OTC: NSHSF) is pleased to announce that its flagship subsidiary, NanoSphere Health Sciences, LLC, has been granted Patent No. 9,925.149—which covers the core technology behind the production of the NanoSphere Delivery System™—by the United States Patent and Trademark Office.

The research-proven NanoSphere Delivery System™, protected by this patent, is one of the most important advancements for the non-invasive delivery of biological agents in over 25 years. The patent broadly encompasses the formation and manufacturing of the NanoSphere Delivery System for the delivery of cannabinoids, pharmaceuticals, nutraceuticals, cosmeceuticals and other biological agents.

NanoSphere’s groundbreaking NanoSphere Delivery System™ nanoencapsulates a broad range of bioactive compounds in a protective membrane, transporting them rapidly and effectively to the bloodstream and cells for greater efficacy. This delivery platform is a breakthrough in pharmaceutical, cannabinoid, nutraceutical and cosmeceutical supplement delivery. It makes the nanoencapsulated agents safer and more bioavailable, reducing adverse effects by delivering precise doses of smart nanoparticles to target sites.

“The granting of the patent for the NanoSphere Delivery System™ secures our position as a leader in advanced nanoparticle delivery,” said Robert Sutton, CEO of NanoSphere Health Sciences. “Major industries have the potential to be reshaped and reimagined by our next-generation technology.”

“NanoSphere’s patent claims and protects our core technology for the formation and manufacturing of lipid, structural nanoparticles, which is the Nanosphere Delivery System™,” said Dr. Richard Clark Kaufman, Chief Science Officer and inventor of the NanoSphere Delivery System™. “This patent extends to our 16 forms of lipid nanoparticle structures, which can be applied across healthcare sectors for vastly improved medical delivery.”

With the issuance of this patent, the NanoSphere will now have long-term market exclusivity over this delivery platform, with patent infringement prohibited. The company intends to license the patented NanoSphere Delivery System™ and proprietary manufacturing process to selected companies in its target industries to maximize commercialization. This patent allows NanoSphere to bring to the world the NanoSphere Delivery System™ through multiple product lines and platforms, such as the company’s cannabis brand Evolve Formulas’ transdermal, intranasal and intraoral applications and beyond.

 

 

Venture Recon (“VentureRecon.com”) is an electronic publication targeted towards independent investors, containing the opinions of our contributors on financial information, including, but not limited to, information on publicly traded companies and the stock market. The information is presented by Venture Recon (“VentureRecon.com”) and can also be based on information supplied by third parties.  The information presented by Venture Recon (“VentureRecon.com”) is for informational purposes only. All articles and commentaries in this email are the result of an independent analysis and, even though we have made efforts in this regard, we cannot guarantee that the information is accurate and complete. The companies mentioned in this email are not responsible for the information that is presented. All information is subject to change, without notice, and Venture Recon (“VentureRecon.com”) is not responsible for updating the information contained in this email.  The information presented is not destined to be, and does not constitute a sales offer nor solicitation of an offer to buy financial investments.  Investors should consult their financial adviser before making any investment decisions concerning the companies mentioned. Our contributors may buy and sell the stocks of these companies.

To Top